Why the study?
To assess weight loss and cardiorenal outcomes by baseline body mass index (BMI) in VERTIS CV.
Does ertugliflozin improve weight loss and cardiorenal outcomes across baseline BMI categories in patients with type 2 diabetes and atherosclerotic cardiovascular disease?
Population
8246 adults with type 2 diabetes and atherosclerotic CV disease
Comparison
Ertugliflozin vs placebo across baseline BMI categories
Design
Post hoc analysis of a randomized controlled trial
Follow-up
5 years
Key result
Ertugliflozin increased the proportion of patients achieving ≥5% body weight reduction at 5 years compared to placebo (34.9% vs 19.4%; OR 2.21, 95% CI 1.76-2.77).
Authors
Loading...
Ertugliflozin delivers sustained weight loss over 5 years in T2D with ASCVD; extends efficacy data across baseline BMI categories.
RCT (n=8,246)
Does ertugliflozin improve weight loss and cardiorenal outcomes across baseline BMI categories in patients with type 2 diabetes and atherosclerotic cardiovascular disease?
Effect estimate: OR 2.21 (95% CI 1.76-2.77)
Absolute Event Rate: 34.9% vs 19.4%
Ertugliflozin provides sustained weight loss and consistent cardiorenal benefits over 5 years in patients with type 2 diabetes and ASCVD, regardless of baseline BMI.
Cosentino et al. (2024) conducted an RCT in Type 2 diabetes and atherosclerotic cardiovascular disease (n=8,246). Ertugliflozin vs. Placebo was evaluated on Achieving ≥5% body weight reduction at 5 years (OR 2.21, 95% CI 1.76-2.77). Ertugliflozin increased the proportion of patients achieving ≥5% body weight reduction at 5 years compared to placebo (34.9% vs 19.4%; OR 2.21, 95% CI 1.76-2.77).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: